Vortioxetine and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Vortioxetine
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You're taking vortioxetine (Trintellix) for your mood and apixaban (Eliquis) to prevent blood clots. Both of these can make it a little easier to bleed, so using them together may raise your bleeding risk a bit more than either one alone.
Vortioxetine affects a chemical called serotonin, which your tiny blood-clotting cells (platelets) use to help stop bleeding. Apixaban already thins your blood. Together, you might notice things like easy bruising, nosebleeds, or bleeding gums. The good news is this is very manageable. Keep taking both exactly as prescribed, watch for unusual bleeding, and let your pharmacist or doctor know if you see anything worrying.
Effect: Additive increase in bleeding risk with coadministration of vortioxetine and apixaban.
Mechanism: Vortioxetine (an SSRI-type agent) depletes platelet serotonin, impairing serotonin-mediated platelet aggregation and hemostasis. This is pharmacodynamic and additive to apixaban's direct factor Xa inhibition. Neither is a prodrug in a way that alters direction; no significant PK interaction was seen (studies with warfarin/aspirin showed no meaningful PK change).
Evidence: Theoretical; severity rated major. Onset unspecified.
- Counsel on signs of bleeding (ecchymosis, epistaxis, petechiae, hematoma).
- Monitor more closely, especially when initiating or discontinuing vortioxetine.
- No routine coagulation assay reliably tracks apixaban effect; rely on clinical monitoring.
What happens
An increased risk of bleeding
Interaction Deep Dive
When vortioxetine, which acts as a serotonin reuptake inhibitor, is given alongside aspirin, warfarin, or other anticoagulants, the likelihood of bleeding events may rise. The combination of SSRIs with antiplatelet drugs can likewise heighten this bleeding risk21. Platelet-released serotonin plays a key role in preserving hemostasis. Bleeding events linked to serotonin reuptake inhibition have been reported and include ecchymosis, hematoma, epistaxis, petechiae, and hemorrhages that are life-threatening. Drug interaction studies found no meaningful pharmacokinetic changes when vortioxetine was combined with either warfarin or aspirin; however, using vortioxetine together with other agents that influence coagulation or bleeding may still elevate bleeding risk. Patients should be watched closely whenever vortioxetine is started or stopped in those already taking medications that disrupt hemostasis. Advise patients about the elevated bleeding risk that comes with concurrent use of vortioxetine and antiplatelet or anticoagulant agents. In patients on warfarin, monitor coagulation indices carefully when vortioxetine is initiated, titrated, or discontinued3.
Why it happens (mechanism)
Release of serotonin by platelets; additive effects on hemostasis
How to manage this interaction
This combination can be used safely with attention. Here is what typically helps:
- Keep taking both as prescribed unless your doctor tells you otherwise.
- Your care team may monitor you more closely, especially when vortioxetine is started, changed, or stopped.
- Watch for and report signs of bleeding: unusual bruising, nosebleeds, bleeding gums, pink or red urine, black stools, or any bleeding that will not stop.
Bring up any new bruising or bleeding with your pharmacist or prescriber. Your doses can be tailored and individualized by your care team if needed.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
4 reports — tap to read
a) A retrospective study of patients older than 50 years diagnosed with acute myocardial infarction (N=27,058) found that SSRI use combined with any antiplatelet therapy significantly raised the risk of bleeding by 1.42-fold relative to aspirin alone. Treatment with aspirin, clopidogrel, and an SSRI significantly elevated the risk by 2.35-fold compared with aspirin alone and by 1.57-fold compared with the combination of clopidogrel and aspirin 1.
b) In a systematic review and meta-analysis comprising 22 observational studies, SSRI use was linked to a significant 1.55-fold rise in the risk of upper gastrointestinal bleeding (UGIB). The simultaneous use of SSRIs and antiplatelet drugs was linked to a 2.48-fold rise in the risk of UGIB (3 studies) 2.
c) Administering multiple daily doses of vortioxetine together with warfarin 1 to 10 mg/day produced no significant effects on prothrombin values, INR, or total warfarin pharmacokinetics (both R- and S-warfarin). Likewise, administering multiple daily doses of vortioxetine together with aspirin 150 mg/day produced no significant effects on platelet aggregation or on the pharmacokinetics of aspirin or salicylic acid 3.
d) Case-control and cohort studies have demonstrated that the concurrent use of selective serotonin and norepinephrine reuptake inhibitors (such as vortioxetine) and antiplatelet agents has been linked to a heightened risk of gastrointestinal bleeding. According to data from published observational studies, exposure to SSRIs, especially during the month prior to delivery, has been linked to a less than 2-fold increase in the risk of postpartum hemorrhage. Reported bleeding events have included epistaxis, ecchymosis, hematoma, petechiae, and life-threatening hemorrhages 3.
Common questions
Can I take Vortioxetine and Apixaban together?
Using vortioxetine with apixaban can add to your bleeding risk, so keep taking both as prescribed and report any unusual bruising or bleeding to your pharmacist or doctor. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Vortioxetine and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Vortioxetine and Apixaban interaction managed?
This combination can be used safely with attention. Here is what typically helps: Keep taking both as prescribed unless your doctor tells you otherwise. Your care team may monitor you more closely, especially when vortioxetine is started, changed, or stopped. Watch for and report signs of bleeding: unusual bruising, nosebleeds, bleeding gums, pink or red urine, black stools, or any bleeding that w… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Vortioxetine or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Labos C, Dasgupta K, Nedjar H, et al: Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183(16):1835-1843. PubMed
- Jiang HY, Chen HZ, Hu XJ, et al: Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13(1):42-50. DOI
- Product Information: TRINTELLIX oral tablets, vortioxetine oral tablets. Takeda Pharmaceuticals America Inc (per FDA), Lexington, MA, 2023. DailyMed
Keep reading about Vortioxetine
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist